Core Viewpoint - Lexaria Bioscience (NASDAQ:LEXX) is experiencing a decline in stock price following the announcement of a direct offering of 2,666,667 shares at a price of $1.50 per share, which is expected to generate gross proceeds of approximately $4.0 million [1] Group 1 - The company announced a sale of 2,666,667 shares with a par value of $0.001 per share [1] - The offering price is set at $1.50 per share [1] - Gross proceeds from the offering are anticipated to be around $4.0 million [1]